EICHOR
● Active Not Recruiting
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Condition: Chronic Obstructive Pulmonary Disease · Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
About this study
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (57)
| SEC Clinical Research, LLC | Dothan, Alabama, United States | — |
| Elite Clinical Studies, LLC | Phoenix, Arizona, United States | — |
| Tucson Clinical Research Institute | Tucson, Arizona, United States | — |
| Downtown LA Research Center Inc - ClinEdge | Los Angeles, California, United States | — |
| California Medical Research Associates, Inc. | Northridge, California, United States | — |
| Northern California Research Corp | Sacramento, California, United States | — |
| Clinical Research of West Florida Inc | Clearwater, Florida, United States | — |
| Fleming Island Center For Clinical Research | Fleming Island, Florida, United States | — |
| Florida Institute For Clinical Research LLC | Orlando, Florida, United States | — |
| Ormond Beach Clinical Research | Ormond Beach, Florida, United States | — |
| Progressive Medical Research | Port Orange, Florida, United States | — |
| Clinical Research of West Florida Inc - Tampa | Tampa, Florida, United States | — |
+ 45 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07016412